Evaluating metabolic features in patients with liver disease
Metabolic Features Effect on FibroScan-AST (FAST) Score in Egyptian Patients With Metabolic-Associated Steatotic Liver Disease (MASLD)
Tanta University · NCT06867419
This study is trying to see how different metabolic factors affect liver health in people with a specific liver disease called MASLD in Egypt.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 385 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University (other) |
| Locations | 1 site (Tanta, Gharbyea) |
| Trial ID | NCT06867419 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess how metabolic features influence the FAST score in patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) in Egypt. Researchers will identify metabolic risk factors and evaluate their impact on stratifying MASLD patients based on predicted FAST scores. Participants will undergo a series of assessments including clinical examinations, laboratory tests, abdominal ultrasonography, and transient elastography to measure liver stiffness and controlled attenuation parameters. The study will calculate the NAFLD fibrosis score and FAST score to better understand liver health in these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with MASLD who have steatosis detected by elastography.
Not a fit: Patients with significant alcohol consumption, viral hepatitis, autoimmune hepatitis, other metabolic liver diseases, or hepatic focal lesions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the stratification and management of MASLD patients, leading to better treatment outcomes.
How similar studies have performed: While there is ongoing research in this area, the specific approach of evaluating metabolic features' effects on FAST score in MASLD patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients with MASLD who had steatosis detected by (VCTE-CAP) elastography Exclusion Criteria: * Patients with a history of significant alcohol consumption more than 30 g/day in men and \> 20 g/day in women. * Patients with positive hepatitis B or C virus markers. * Patients with autoimmune hepatitis. * Patients with any other metabolic liver disease. * Patients with hepatic focal lesions.
Where this trial is running
Tanta, Gharbyea
- Tanta University Hospitals — Tanta, Gharbyea, Egypt (RECRUITING)
Study contacts
- Study coordinator: Rania M Elkafoury, MD
- Email: rania.elkafoury@med.tanta.edu.eg
- Phone: +201004672358
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic dysfunction-Associated Steatotic Liver Disease, FAST Score, Metabolic Features